Associate researcher in Leukaemia Cell Quiescence and Treatment Resistance

EURAXESS hosting organisation · Multiple European countries

Description of the workplace The research group is part of the Division of Molecular Medicine and Gene Therapy within the Faculty of Medicine, Lund University. In childhood B-cell acute lymphoblastic leukaemia (B-ALL), a subset of leukaemic cells survives chemotherapy by entering a dormant, quiescent state. These cells are thought to contribute to minimal residual disease and ultimately drive relapse. The group investigates the mechanisms underpinning this process using a human induced pluripotent stem cell (iPSC)-derived bone marrow organoid model engrafted with primary ALL cells, enabling the study of leukaemia-niche interactions that govern entry into quiescence. This platform is combined with an expressed barcode system that enables simultaneous tracking of lineage, cell state, and cel

Funding and what it does not cover

Funding details were taken from the official programme page text. Confirm the current call before applying.